Mastodawn

In 2012, Genelife published a perspective on drug–device combination products.

The conclusion then: the benefits justify the complexity. The manufacturing model that made most sense: two distinct facilities, coordinated but separate.

Our updated perspective — what's changed, what hasn't, and what it means for your program — is now on the blog.